55 citations
,
December 2006 in “Journal of The American Academy of Dermatology” This review discusses the potential for SSRIs to cause serious skin reactions and suggests considering alternative antidepressants if such reactions occur.
25 citations
,
January 2006 in “Pharmacoepidemiology and drug safety” This study concluded that alopecia is a rare side effect of SSRIs, with sertraline showing a higher association compared to citalopram, particularly among women.
July 2023 in “World Journal of Biology Pharmacy and Health Sciences” This research suggests that the drugs trazodone and chlorpromazine, which have effects on specific receptors, may help restore libido synaptic circuits and potentially treat sexual dysfunction associated with post-SSRI and post-finasteride syndromes.
September 2025 in “Healthcare” This review discusses the off-label use of SSRIs to manage inappropriate sexual behavior in elderly dementia patients and highlights the unclear risk of post-SSRI sexual dysfunction, noting a need for high-quality clinical trials.
July 2023 in “Zenodo (CERN European Organization for Nuclear Research)” In this study, the authors propose that drugs like trazodone and antipsychotics such as chlorpromazine, which can induce priapism, may help restore libido synaptic circuits, offering potential treatment for post-finasteride syndrome and post-SSRI sexual dysfunction.